Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.52 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | PGK2 | P07205 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28545579 | 1.00 | PGD (0.55) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL16416132 | 0.89 | PGD (0.61) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL5000804 | 0.89 | PGD (0.61) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL1533840 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL17285 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL428503 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL1403636 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL939456 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL20817087 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 | |
| SCHEMBL3515615 | 0.81 | PGD (0.53) | PGDMPIPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2061480-A2 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008076156-A2 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | GLMN, RNGTT, GMPS | PGD 371/4885MPI 1155/4885PGK1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.